Success Metrics

Clinical Success Rate
83.3%

Based on 5 completed trials

Completion Rate
83%(5/6)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(10%)

Phase Distribution

Ph phase_2
1
10%
Ph phase_1
1
10%
Ph phase_3
1
10%
Ph not_applicable
6
60%
Ph phase_4
1
10%

Phase Distribution

1

Early Stage

1

Mid Stage

2

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
1(10.0%)
Phase 2Efficacy & side effects
1(10.0%)
Phase 3Large-scale testing
1(10.0%)
Phase 4Post-market surveillance
1(10.0%)
N/ANon-phased studies
6(60.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

62.5%

5 of 8 finished

Non-Completion Rate

37.5%

3 ended early

Currently Active

0

trials recruiting

Total Trials

10

all time

Status Distribution
Active(1)
Completed(5)
Terminated(3)
Other(1)

Detailed Status

Completed5
Withdrawn2
Not yet recruiting1
unknown1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
0
Success Rate
83.3%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (10.0%)
Phase 21 (10.0%)
Phase 31 (10.0%)
Phase 41 (10.0%)
N/A6 (60.0%)

Trials by Status

not_yet_recruiting110%
unknown110%
completed550%
withdrawn220%
terminated110%

Recent Activity

Clinical Trials (10)

Drug Details

Intervention Type
DRUG
Total Trials
10